| |
 |

 |
Lakeshore Capital Partners represents the capital and talent comprised of executives, advisors, and entrepreneurs who have decades of experience operating large and small businesses, in a variety of industries, from start-ups to Fortune 500 companies.
Andrew Matricaria, Managing Partner
Prior to co-founding Lakeshore Capital Partners, Andrew worked as Product Manager at Amgen, a leading human therapeutics company in the biotechnology industry. Andrew was a participant in and graduate of Amgen's Commercial Leadership Program, a three-year program designed to develop future commercial leaders. While at Amgen, Andrew took on increasing levels of responsibility in the sales and marketing organization. In his most recent role, he directed the strategic planning and operations function for a groundbreaking oncology product launch. Previous to Amgen, Andrew worked as an investment banking analyst for Credit Suisse. In this role, he developed a comprehensive working knowledge of the analysis, structure and execution of public equity offerings, public debt offerings, mergers, acquisitions and divestitures as a member of client advisory teams. Andrew's work experience also includes an investment banking summer internship at Goldman Sachs. Andrew holds a BA from the University of Michigan and an MBA from The Fuqua School of Business at Duke University.
Lee Matricaria, Managing Partner
Prior to co-founding Lakeshore Capital Partners, Lee spent 12 years at St. Jude Medical, a leader in the medical device industry. His responsibilities included designing, implementing, and managing IDE clinical trials for next-generation Cardiac Rhythm Management products, including implantable cardioverter defibrillators, cardiac pacemakers, and delivery tools. In his most recent role, Lee was a Field Clinical Engineer working with key physician opinion leaders, providing clinical expertise, and developing business strategies to drive long term growth. During his time at St. Jude Medical, he increased productivity, throughput, reliability of processes, customer satisfaction, and is a named author on multiple patent submissions and abstracts. Previously, Lee worked at Boston Scientific (Guidant) with sales and implant case coverage responsibilities as well as clinician training. Lee is also a successful entrepreneur who has co-founded and operated Wit's End Gifts (witsendgifts.com), a leader in corporate and online incentives and gifts. Lee is a graduate of Marquette University.
Michael J. Coyle, Limited Partner
Michael J. Coyle is currently a consultant on device related issues to various clients in the Medical Device, Venture Capital and Private Equity communities. He also serves on the Board of Directors of VNUS Medical Technologies, Inc., the global market leader in endovenous vein therapies. From 1994 to 2007, Mr. Coyle served in various senior leadership positions with St. Jude Medical, Inc. From 2001 to 2007, he served as President of the St. Jude Medical Cardiac Rhythm Management Division. Mr. Coyle joined St. Jude Medical in 1994 as Director, Business Development. He was named President of the company's Daig catheter division in January 1997. Prior to joining St. Jude, Mr. Coyle spent nine years with Eli Lilly and Company in a variety of technical and business roles in both its Pharmaceutical and Medical Device Divisions, including Marketing Manager-Diabetes Care Products, Business Development Associate/Manager-Medical Devices & Diagnostics Division, Biomedical Research Engineer-Toxicology Division and Process Design Engineer-Pharmaceutical Manufacturing. Mr. Coyle received his B.S. degree in Chemical Engineering from Case Western Reserve University and an M.B.A. from the Wharton School of the University of Pennsylvania. He is an inventor on six issued U.S. patents.
James C. Gilstrap, Limited Partner
James C. Gilstrap is Chairman of CardioDynamics International Corporation, a medical device company that manufactures noninvasive cardiac heart monitors. Mr. Gilstrap also has more than forty years of investment experience. His start up investment in WebMD.com has led to a network of new investment ideas and partners. Mr. Gilstrap also serves as a Director or Managing Member of several other companies, including: Abbott Investment Company, LLC, Clique Capital, LLC, and Bull Durham, LLC. In 1956, James Gilstrap joined the First Southwest Company of Investment Bankers in Dallas, Texas. In 1969, he left First Southwest Company to start an “Over the Counter” operation at Jefferies and Company in Los Angeles, California. As Senior Executive Vice President, Mr. Gilstrap was part of the management team that built Jefferies and Company into the largest “Third Market” (the trading of listed stocks over the counter) in the world. Mr. Gilstrap retired from Jefferies in 1987. Mr. Gilstrap is a past President of the Dallas Securities Dealers, as well as a past member of the Board of Governors of the National Association of Securities Dealers, Inc.
John R. Larson, Limited Partner
John R. Larson has over 30 years of experience in the securities, finance and technology areas. As a practicing attorney, he has participated in over $2 billion of debt and equity financings for both public and private entities. Mr. Larson was a founder of Prolifaron, Inc., an early stage biotechnology company started in 1997 and sold to Alexion Pharmaceuticals, Inc. in 2000, and a founder of Materia, Inc., a research and development company specializing in new applications of patented polymer products. Since December 1999, he has served as Managing Director of Clique Capital, LLC, a venture capital group focused in the healthcare and technology areas. In addition, he is a Senior Vice-President and Secretary of Northland Securities, Inc. Mr. Larson has served as Commissioner of Securities and Chairman of the Commerce Commission for the State of Minnesota. He also serves as an officer and director of Armada Media Corporation, a privately held company that owns and operates radio stations in small and medium sized markets. Mr. Larson holds a B.A. degree from Minnesota State University and a J.D. from William Mitchell College of Law.
Gregory T. Lucier, Limited Partner
Gregory T. Lucier has served as Chief Executive Officer of Invitrogen and member of the board of directors since May 2003. In April 2004 he was appointed Chairman of the Board of Directors. From June 2000 to May 2003, Mr. Lucier was the President and Chief Executive Officer of GE Medical Systems Information Technologies. Mr. Lucier was named a corporate officer of General Electric Corporation (GE) in 1999 by that company's board of directors and served in a variety of leadership roles during his career at GE including as Vice President Global Services, GE Medical Systems. Mr. Lucier is currently Chairman of BIOCOM, serves on the BIO Board of Directors as well as on the board of the Burnham Institute of Medical Research. He is actively involved at San Diego State as a distinguished lecturer. He received his B.S. in Engineering from Pennsylvania State University and an M.B.A. from Harvard Business School.
Ronald A. Matricaria, Limited Partner
Ron has over 35 years of medical device and pharmaceutical experience at St. Jude Medical, Inc. and Eli Lilly and Company, Inc. From April 1993 to May 1999, he served as president and chief executive officer of St. Jude Medical, Inc. and was elected chairman of the board of directors in January 1995. Prior to joining St. Jude Medical, Mr. Matricaria spent 23 years with Eli Lilly and Company, Inc. His last position was executive vice president of the Pharmaceutical Division of Eli Lilly and Company and president of its North American operations. He also served as president of Eli Lilly International Corporation, as well as President of its Medical Device Division. Mr. Matricaria currently serves on the boards of Hospira Corporation, Invitrogen, Inc. and Volcano Inc. Mr. Matricaria holds a bachelor's degree in pharmacy from Massachusetts College of Pharmacy and was awarded an honorary Doctor of Science degree in pharmacy in recognition of his contributions to the practice of pharmacy. In 2002 he was also recognized with a Medical Device Industry "Life Time Achievement" award.
Curt Thompson, Limited Partner
Curt Thompson is a Principal of Hirtle, Callaghan & Co., a Registered Investment Advisor based in suburban Philadelphia. Hirtle Callaghan serves as an independent, completely objective “outsourced Chief Investment Officer and fully staffed investment department” to high net worth family groups, endowment, foundations, and Charitable Trusts. The firm currently represents about 375 clients supervising a total of $17 billion of investable assets. Curt is a 14 year veteran of the firm and is the managing partner of Hirtle Callaghan's southwest regional office in Phoenix. Prior to moving to Phoenix in January 2002, Curt co-managed Hirtle Callaghan's mid-Atlantic regional office. Curt earned a B.S. and M.B.A. from the Pennsylvania State University. He serves on Hirtle Callaghan's internal Investment Policy Committee that is responsible for developing asset allocation policies for clients and interviewing and recommending asset managers (public, hedge fund, private equity).
John D. Thompson, Limited Partner
John D. Thompson was Senior Vice President of Corporate Development for Invitrogen Corporation until he retired in late 2007. Appointed to the position in 2003, he oversaw the company's growth strategies through licensing, mergers, acquisitions, and other collaborations. Previously at Invitrogen, Mr. Thompson served as Vice President of Corporate Development from 2000 to 2003. Prior to joining Invitrogen, Mr. Thompson was Senior Vice President of Strategic and Business Development from 1995 to 2000 for Dexter Corporation, a specialty materials manufacturer, and held various other executive positions at the company from 1991 to 1995. From 1979 to 1991, he held several executive financial and general management positions at Life Technologies, a biotechnology firm. Mr. Thompson holds a Bachelor of Science degree in business administration from Cleveland State University.
Jon Kreidler, CFA, Advisor
Jon is an analyst at Waterstone Capital Management, a convertible arbitrage hedge fund located outside of Minneapolis, MN. Prior to his current position, Mr. Kreidler worked for Piper Jaffray & Co., an investment bank, where he specialized in transactions involving mergers and acquisitions across multiple sectors. Prior to that position, Mr. Kreidler worked for The Northern Trust Company where he worked with the bank's distressed loan portfolio, focusing on workouts and restructuring corporate credits. Mr. Kreidler graduated with a bachelor's degree in economics from the University of Michigan and received a Master of Business Administration degree with Honors from the University of Chicago Graduate School of Business with concentrations in finance and accounting. He is also a Chartered Financial Analyst.
Stuart Larkins, Advisor
Stuart has more than 15 years of operations experience in the services industry. He has spent the last eight years at Performics, an internet start up, leading the business through rapid growth and strategic acquisitions by DoubleClick, Hellman & Freeman, and most recently, Google. In his current role as Senior Vice President Operations, Stuart oversees a team of search engine marketing experts and leads Performics' interactions with major search engines. His team manages search marketing programs for hundreds of clients in diverse industries including automotive, financial services and retail. Before joining DoubleClick Performics, Stuart served as Operations Manager for Penske Truck Leasing, a GE Capital Company. Prior to his operations management role, Stuart functioned as a Project Manager and served as a Black Belt during the initial wave of GE's Six-Sigma Initiative. He began his career as a Special Aide to U.S. Senator Spencer Abraham. Stuart holds a BS in Economics from Southern Methodist University.
Walter L. Sembrowich, Ph.D., Advisor
Dr. Sembrowich co-founded Travanti Pharma and has been a Director, Chairman of the Board and formerly Chief Executive Officer since 1999. From 1995 to 1999, he was President of Aviex Inc., an investment and management firm serving start-up and early stage medical companies. In 1990, Dr. Sembrowich co-founded Diametrics Medical, Inc., a manufacturer of point-of-care blood gas and electrolyte systems, where he served as CEO until 1993 and as Co-Chairman of the Board until 1996. He was a co-founder of Arden Medical Systems, Inc., a manufacturer of doctor's office chemistry systems, and served as Vice President of Scientific Affairs and Director from 1983-1988. He is a Director of EMVascular Inc, an early stage cardiovascular technology company. Dr. Sembrowich received a BS from Boston University, MS from Illinois State University, and PhD from Washington State University. He was the recipient of an N.I.H. post-doctoral fellowship. He has numerous patents and publications in the fields of medical technology, applied physiology and drug delivery.
|
|
|
|
|
|